- Home
- VALN vs TKNO Comparison
VALN vs TKNO Comparison
Compare VALN & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VALN
- TKNO
- Stock Information
- Founded
- VALN 2012
- TKNO 1996
- Country
- VALN France
- TKNO United States
- Employees
- VALN N/A
- TKNO N/A
- Industry
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- VALN Health Care
- TKNO Health Care
- Exchange
- VALN Nasdaq
- TKNO Nasdaq
- Market Cap
- VALN 332.0M
- TKNO 390.7M
- IPO Year
- VALN 2021
- TKNO 2021
- Fundamental
- Price
- VALN $3.76
- TKNO $8.50
- Analyst Decision
- VALN Strong Buy
- TKNO Buy
- Analyst Count
- VALN 2
- TKNO 2
- Target Price
- VALN $18.50
- TKNO $5.00
- AVG Volume (30 Days)
- VALN 30.5K
- TKNO 227.3K
- Earning Date
- VALN 11-07-2024
- TKNO 11-07-2024
- Dividend Yield
- VALN N/A
- TKNO N/A
- EPS Growth
- VALN N/A
- TKNO N/A
- EPS
- VALN N/A
- TKNO N/A
- Revenue
- VALN $176,817,979.00
- TKNO $36,347,000.00
- Revenue This Year
- VALN $24.30
- TKNO $3.47
- Revenue Next Year
- VALN $16.05
- TKNO $12.07
- P/E Ratio
- VALN N/A
- TKNO N/A
- Revenue Growth
- VALN N/A
- TKNO N/A
- 52 Week Low
- VALN $3.65
- TKNO $1.16
- 52 Week High
- VALN $10.76
- TKNO $8.91
- Technical
- Relative Strength Index (RSI)
- VALN 37.11
- TKNO 60.68
- Support Level
- VALN $3.62
- TKNO $7.56
- Resistance Level
- VALN $4.09
- TKNO $8.89
- Average True Range (ATR)
- VALN 0.20
- TKNO 0.62
- MACD
- VALN 0.03
- TKNO 0.04
- Stochastic Oscillator
- VALN 39.44
- TKNO 74.31
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.